(E)-2-(3-(3-Methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)benzoic acid

Name: (E)-2-(3-(3-Methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)benzoic acid | 1001288-58-9
Brand: US-CATO
SKU: S57C1002021_20_MG
Price: 19998.0 USD
Availability: OutOfStock

Cat. No S57C1002021_20_MG

Vendor: US-CATO

Product Information

Product Name

(E)-2-(3-(3-Methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)benzoic acid

Brand Name

US-CATO

Product Number

C1002021

CAS

1001288-58-9

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

23648966

IUPAC Name

2-(E)-3-(3-methoxy-4-prop-2-ynoxyphenyl)prop-2-enoylaminobenzoic acid

InChI Key

UIWZIDIJCUEOMT-PKNBQFBNSA-N

SMILES

COC1=C(C=CC(=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OCC#C

References Data Source From Pubchem

FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy

Publication Name: PLOS ONE

Publication Date: 2015-07-29

DOI: 10.1371/journal.pone.0134392

A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction

Publication Name: International Journal of Cardiology

Publication Date: 2013-09-30

DOI: 10.1016/j.ijcard.2012.11.067

Attenuation of Armanni–Ebstein lesions in a rat model of diabetes by a new anti-fibrotic, anti-inflammatory agent, FT011

Publication Name: Diabetologia

Publication Date: 2012-12-16

DOI: 10.1007/s00125-012-2805-9

A Purpose-Synthesised Anti-Fibrotic Agent Attenuates Experimental Kidney Diseases in the Rat

Publication Name: PLoS ONE

Publication Date: 2012-10-10

DOI: 10.1371/journal.pone.0047160

FT011, a New Anti-Fibrotic Drug, Attenuates Fibrosis and Chronic Heart Failure in Experimental Diabetic Cardiomyopathy

Publication Name: European Journal of Heart Failure

Publication Date: 2012-05-01

DOI: 10.1093/eurjhf/hfs011

(E)-2-(3-(3-Methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)benzoic acid

Product Information

General Information

References Data Source From Pubchem

FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy

A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction

Attenuation of Armanni–Ebstein lesions in a rat model of diabetes by a new anti-fibrotic, anti-inflammatory agent, FT011

A Purpose-Synthesised Anti-Fibrotic Agent Attenuates Experimental Kidney Diseases in the Rat

FT011, a New Anti-Fibrotic Drug, Attenuates Fibrosis and Chronic Heart Failure in Experimental Diabetic Cardiomyopathy